The recommended dose of secukinumab for patients with PsA and axSpA is 150 mg (300 mg in patients with PsA and concomitant moderate-to-severe plaque psoriasis or an inadequate response to a TNF-α inhibitor), with the possibility of increasing to 300 mg as needed. Here, TNF is linked to psoriasis vulgaris.